Doxorubicin‐Conjugated Iron Oxide Nanoparticles: Surface Engineering and Biomedical Investigation. Issue 6 (4th June 2020)

• Record Type: Journal Article
• Authors: Oleksa, Viktoriia; Macková, Hana; Patsula, Vitalii; Dydowiczová, Aneta; Janoušková, Olga; Horák, Daniel
• Is Part Of: ChemPlusChem. Volume 85:Issue 6(2020)
• Page Start: 1156
• Page End: 1163
• Publication Date: 2020-06-04
• Subjects: antitumor agents -- cytotoxicity -- drug delivery -- magnetic properties -- nanoparticles; Chemistry -- Periodicals; 540.5
• DOI: 10.1002/cplu.202000360
• Languages: English
• ISSNs: 2192-6506

Abstract

Abstract: Development of therapeutic systems to treat glioblastoma, the most common and aggressive brain tumor, belongs to priority tasks in cancer research. We have synthesized colloidally stable magnetic nanoparticles ( D h =336 nm) coated with doxorubicin (Dox) conjugated copolymers of N, N ‐dimethylacrylamide and either N ‐acryloylglycine methyl ester or N ‐acryloylmethyl 6‐aminohexanoate. The terminal carboxyl groups of the copolymers were reacted with alendronate by carbodiimide formation. Methyl ester groups were then transferred to hydrazides for binding Dox by a hydrolytically labile hydrazone bond. The polymers were subsequently bound on the magnetic nanoparticles through bisphosphonate terminal groups. Finally, the anticancer effect of the Dox‐conjugated particles was investigated using the U‐87 glioblastoma cell line in terms of particle internalization and cell viability, which decreased to almost zero at a concentration of 100 μg of particles per ml. These results confirmed that poly( N, N ‐dimethylacrylamide)‐coated magnetic nanoparticles can serve as a solid support for Dox delivery to glioblastoma cells. Abstract : Special delivery : Modification of monodisperse magnetic nanoparticles ( D h =21 nm) with poly[ N, N ‐dimethylacrylamide‐ co ‐ N ‐(2‐hydrazinyl‐2‐oxoethyl)acrylamide]‐aledronate‐doxorubicin provided composite particles of increased size ( D h =336 nm), positive ξ‐potential (34.7 mV), and containing 37.2 μg of doxorubicin per mg of iron oxide. The particles were internalized in U‐87 human glioblastoma cells, releasing Dox at acidic pH and effectively decreasing cell viability.